Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cells + Chemotherapy in Advanced Solid Tumors
NCT04214730Unknown
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Trial in solid tumor (2 arms), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Disease Control Rates at 1 year. Status: unknown.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04214730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04214730.